ArticleBMC veterinary research2025
Saccharomyces cervisiae ameliorative impact combined with sulfaclozine on broiler chicken oxidative status.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chicken hepatic injury and food safety: From etiological drivers to pathogenic mechanisms.Poultry science · 2026Review
- Antioxidant chemistry and its role in mitigating oxidative stress in animals.Open veterinary journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Poultry production has expanded, and imports from other countries have surged due to the sharp growth in demand for chicken meat. The purpose of this study was to determine the effect of different doses of sulfaclozine 30%, either alone or in conjunction with Saccharomyces cerevisiae (yeast), on body weight gain, biochemical markers, oxidative status, and histopathological variation in broilers' organs. One hundred fourteen -day-old chicks were divided into five groups for this experiment (20 each). For a total of 20 days, the first group was used as a control; the second group received 30 mg/kg of sulfaclozine; the third group received 70 mg/kg; the fourth group received 1.5 g/L of Saccharomyces cerevisiae followed by 30 mg/kg of sulfaclozine; and the final group received 70 mg/kg of sulfaclozine after taken 1.5 g/L of Saccharomyces cerevisiae. Hepatic and renal functions, along with malonaldehyde levels, were much higher in the chickens that received 70 mg/kg of sulfaclozine followed by 30 mg/kg; however, total protein, albumin, and catalase levels were much lower, and signs of liver and kidney damage were seen. On the other hand, the groups that received sulfaclozine treatments subsequent Saccharomyces cerevisiae showed improved metabolic indices and a partial recovery from the histopathological change.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.